HighTower Advisors LLC Has $366,000 Stock Position in Glaukos Corporation $GKOS

HighTower Advisors LLC boosted its position in shares of Glaukos Corporation (NYSE:GKOS) by 12.9% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,722 shares of the medical instruments supplier’s stock after purchasing an additional 424 shares during the period. HighTower Advisors LLC’s holdings in Glaukos were worth $366,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Primecap Management Co. CA increased its holdings in shares of Glaukos by 0.3% during the first quarter. Primecap Management Co. CA now owns 1,218,475 shares of the medical instruments supplier’s stock worth $119,922,000 after buying an additional 4,150 shares in the last quarter. Westfield Capital Management Co. LP increased its holdings in Glaukos by 34.3% during the 1st quarter. Westfield Capital Management Co. LP now owns 1,084,184 shares of the medical instruments supplier’s stock valued at $106,705,000 after purchasing an additional 277,033 shares in the last quarter. Northern Trust Corp increased its holdings in Glaukos by 7.4% during the 4th quarter. Northern Trust Corp now owns 578,673 shares of the medical instruments supplier’s stock valued at $86,766,000 after purchasing an additional 40,052 shares in the last quarter. Principal Financial Group Inc. raised its position in Glaukos by 21.8% in the 1st quarter. Principal Financial Group Inc. now owns 327,036 shares of the medical instruments supplier’s stock valued at $32,187,000 after purchasing an additional 58,502 shares during the last quarter. Finally, Nuveen LLC acquired a new position in Glaukos in the first quarter worth $31,474,000. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Glaukos Stock Performance

Glaukos stock opened at $95.86 on Tuesday. The company has a market cap of $5.50 billion, a PE ratio of -58.10 and a beta of 0.77. The company has a current ratio of 5.51, a quick ratio of 4.69 and a debt-to-equity ratio of 0.09. Glaukos Corporation has a 1 year low of $77.10 and a 1 year high of $163.71. The company’s 50-day moving average is $95.60 and its two-hundred day moving average is $98.45.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.02. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The business had revenue of $124.12 million during the quarter, compared to the consensus estimate of $115.49 million. During the same period in the previous year, the firm posted ($0.52) earnings per share. Glaukos’s revenue for the quarter was up 29.7% compared to the same quarter last year. Glaukos has set its FY 2025 guidance at EPS. Equities analysts anticipate that Glaukos Corporation will post -1.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on GKOS. BTIG Research restated a “buy” rating on shares of Glaukos in a research note on Monday, July 14th. William Blair raised shares of Glaukos to a “strong-buy” rating in a report on Thursday, July 31st. Wells Fargo & Company boosted their target price on shares of Glaukos from $86.00 to $92.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 31st. Zacks Research lowered shares of Glaukos from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 15th. Finally, Mizuho set a $130.00 price target on shares of Glaukos in a report on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $127.42.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.